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There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strat-
egies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are
not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection
against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-
mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses
to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we
challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mecha-
nisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine develop-
ment strategies.The Need for New TB Vaccines
Approximately one-third of the world’s population is infected
with Mycobacterium tuberculosis (M.tb), leading to an asymp-
tomatic state referred to as latent tuberculosis infection (LTBI).
About 10% of people with LTBI subsequently develop the
disease tuberculosis (TB), a risk that can be up to 30 times higher
in the setting of immunodeficiency such as that caused by HIV
infection (World Health Organization, 2012). Consequently, an
estimated 8.8 million new TB cases are currently reported annu-
ally, with 1.1 million TB-associated deaths among HIV-unin-
fected and 0.35 million among HIV coinfected people (World
Health Organization, 2012). The available vaccine in the form of
an attenuated Mycobacterium bovis Bacillus Calmette-Gue´rin
(BCG) strain is clearly inadequate, and a more effective vaccine
against active TB is urgently needed.
An ‘‘ideal’’ antituberculous vaccine would protect against
both infection with M.tb in exposed persons and the develop-
ment of disease in those who have already been infected. The
current BCG vaccine has limited protective capacity. Its
main effect is partial protection against disseminated TB during
early childhood with little or no impact on the development of
‘‘reactivation’’ TB later in life (reviewed in Colditz et al., 1994).
Furthermore, this vaccine appears to have variable effective-
ness due to considerable batch-to-batch variations as well as
differences in BCG strains utilized for vaccination (Keyser
et al., 2011). In addition, the BCG vaccine does not prevent
infection with M.tb. Nevertheless, this vaccine has been in
use for almost a century and remains the only approved vaccine
against TB.
Historically the most effective antimicrobial vaccines protect
the host by generating antibody responses that neutralize the
initial inoculum to prevent the establishment of infections
(Robbins et al., 1995). In fact, all approved vaccines against
bacterial pathogens, except for M.tb, are believed to mediate
protection by generating an antibody response that neutralizes
the infecting inoculum (Robbins et al., 1995). Unfortunately, it250 Cell Host & Microbe 13, March 13, 2013 ª2013 Elsevier Inc.has been difficult to apply this successful formula for protec-
tion against TB because infection fails to consistently elicit
protective Abs to M.tb (Glatman-Freedman, 2006). A clinically
highly relevant alternative would be a vaccine that would
not protect against infection but would prevent disease. The
association of TB with granuloma progression to caseous
necrosis suggests that a vaccine that could promote and
enhance local containment might prevent both disease and
transmission. In this regard, the fact that humoral immunity is
a potent mediator of inflammation, and that some antibodies
downregulate inflammation (Buccheri et al., 2007), suggests
that vaccines eliciting inflammation-modulating antibodies
could protect by preventing granulomas from progressing to
caseous necrosis. Such a vaccine is theoretically possible
even though there is no precedent for this among licensed
products. In this strategy the protective effect would be medi-
ated by better control of mycobacteria in the granuloma
through the addition of antibody effector mechanisms and/or
better-organized granulomas.
Several new TB vaccines and vaccination approaches are in
development, and many of those are presently at various stages
in clinical trials. These have been extensively reviewed else-
where (Checkley and McShane, 2011; Kaufmann, 2011) and
will not be discussed in detail here. Most of the new vaccination
strategies focus on either improving the current BCG vaccine or
boosting it with a second dose of BCG or a different TB vaccine.
However, all of these strategies have in common the goal of
targeting the enhancement of cell-mediated immunity against
M.tb. While there is no doubt that cell-mediated immunity is
a major component in the control of mycobacterial infection,
there are now compelling data showing that protective Abs
against mycobacteria exist as discussed here and previously
described (Abebe and Bjune, 2009; Glatman-Freedman, 2006;
Glatman-Freedman and Casadevall, 1998). Such data suggest
that enhanced TB vaccine effectiveness could be achieved
by including approaches that, in addition to cell-mediated
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that elicit responses from both arms of the adaptive immunity
maywork synergistically, given the interconnectedness between
humoral and cellular immunity. However, antibody-based
vaccine approaches are still not being considered in the
design of vaccines against TB. This is due to several factors
that range from inadequate understanding of the efficacy of
antibody-mediated immunity against intracellular pathogens, to
the notion that, given that Th1-type responses are critical for
containment of intracellular infection, a vaccine must work
through that mechanism for efficacy. This Perspective will reap-
praise and update the increasing evidence of antibody-mediated
immunity against M.tb, explore potential mechanism of protec-
tion, and challenge the common belief that immunity against
M.tb relies solely on cellular defense mechanisms. Due to the
wealth of literature and prior reviews, we focus predominantly
on studies published more recently. For a summary of earlier
studies, we refer the reader to an earlier review (Glatman-
Freedman and Casadevall, 1998). At the end of this Perspective,
we propose a paradigm shift and propose that induction of anti-
body-mediated immunity should be included in TB vaccine
development strategies.
The Human Humoral Immune Response to TB
The field of TB serology provides abundant data showing that
M.tb induces a humoral immune response to a wide variety
of mycobacterial antigens in humans despite being an intracel-
lular pathogen (reviewed in Steingart et al., 2009). Furthermore,
several studies have demonstrated that intradermal BCG vacci-
nation elicits IgG and IgM responses to several mycobacterial
antigens, and especially to the glycolipid lipoarabinomannan,
a major cell wall antigen (Beyazova et al., 1995; Brown et al.,
2003; de Vallie`re et al., 2005). Some of these antibody responses
were also shown to enhance both innate and cell-mediated
immune responses against mycobacteria (de Vallie`re et al.,
2005).
The humoral immune response to mycobacterial antigens
differs depending on the state of infection (reviewed in Kun-
nath-Velayudhan and Gennaro, 2011). For example, individuals
with LTBI, considered to not have active TB, have Abs to
a much smaller and partially different repertoire of M.tb antigens
than those with TB. Furthermore, data in both animals and
humans indicate that the height of antibody titers correlates
with the degree of mycobacterial burden (Achkar et al., 2010;
Kunnath-Velayudhan et al., 2010; Yu et al., 2012). The observa-
tion of high antibody titers against mycobacterial antigens in
patients with the disease has historically supported the argu-
ment that these antibodies must be nonprotective. Paradoxi-
cally, the same type of reasoning is not used to challenge the
currently established concept that immunity against TB is mostly
cell and cytokine mediated (i.e., INF-g), since the majority of
patients develop TB despite having normal T cell function and
high INF-g levels. In fact, just as certain antibody titers can serve
as markers for TB, INF-g levels can indicate progression from
infection to disease (Diel et al., 2011; Lin et al., 2009). Although
we concur that many antibodies elicited by M.tb might not be
functional or could even enhance an inflammatory response,
various studies show or suggest that certain antibodies have
protective function against TB.Antibody-Mediated Protection against Intracellular
Pathogens
The efficacy of antibody-mediated immunity against amicrobe is
established by three general approaches singly or in combina-
tion (Casadevall, 2004):
(1) Establish that passive administration of a microbe-
specific antibody modifies the course of infection to the
benefit of the host.
(2) Document an inverse relationship between the presence
of microbe specific antibody in a host and susceptibility
to infection and disease.
(3) Establish increased susceptibility to disease in hosts with
deficits in humoral immunity and/or B cell function.
Until relatively recently it was not possible to consistently
establish any of these criteria for a role of antibody-mediated
immunity in protection against TB. The inability to obtain positive
evidence combined with the overwhelming evidence for a strong
role for cell-mediated protection set up a false dichotomy which
posited no role for humoral immunity while assigning all protec-
tive function to cell-mediated immunity. It is noteworthy that
this belief also represented a logical error in assuming that
the absence of experimental evidence for antibody-mediated
immunity implied no role for antibody in host defense. Further
obscuring the analysis was the notion that since M.tb was an
intracellular pathogen it was outside the reach of antibody effi-
cacy because immunoglobulins are extracellular molecules.
However, this relatively simplistic view missed the numerous
mechanisms by which antibody-mediated immunity could
modify the outcome of bacterial intracellular pathogenesis
through effects ranging from opsonization to activation of FcR
(Casadevall, 2003).
Like mycobacteria, many of the medically relevant fungi
such asC. neoformans andHistoplasma capsulatum are faculta-
tive intracellular pathogens, and control of infection requires
vigorous granuloma formation indicative of cell-mediated immu-
nity. Like the field of TB, the field of mycology once regarded
humoral immunity to have no role in protection against fungi,
but this dogma was unraveled by the application of hybridoma
technology, which revealed the existence of protective mono-
clonal antibodies (mAbs; reviewed in Casadevall, 1995). Two
decades later, humoral immunity had been shown to be protec-
tive against numerous fungi (reviewed in Casadevall and Pirofski,
2012a), and two vaccines against C. albicans are currently in
clinical trials, both of which are believed to mediate protection
by eliciting protective humoral immunity (reviewed in Cassone
and Casadevall, 2012). Furthermore, similar debates had gone
on in other fields involving intracellular pathogens such as
Salmonella spp., and yet vaccines were ultimately developed
and licensed that protected through antibody-mediated immu-
nity (Collins, 1974).
The precedents with medically relevant fungi and Salmonella
spp. are relevant to the mycobacterial field because they estab-
lish that failure to elicit a protective antibody response and
an inability to demonstrate the efficacy of antibody-mediated
protection by the conventional methodology do not negate the
absence of protective antibodies and the possibility of designing
vaccines that mediate protection by eliciting protective anti-
body responses. We believe that sufficient information for theCell Host & Microbe 13, March 13, 2013 ª2013 Elsevier Inc. 251
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now accumulated such that the field has reached a tipping
point with regards to reassessing the mechanisms of immunity
against TB.
The Complexity of Humoral Immunity against TB
The efficacy of humoral immunity against TB has now been
studied for over 100 years, but for most of this time conclusive
evidence has been lacking because animal and human studies
have provided inconsistent and sometimes contradictory data
(reviewed in Glatman-Freedman and Casadevall, 1998). How-
ever, even though the evidence for the efficacy of humoral immu-
nity was inconsistent, the majority of studies in the literature
ranging from the era of serum therapy to immunization with
defined antigens suggested a protective role for antibody (Glat-
man-Freedman and Casadevall, 1998). The problem was not the
absence of studies showing efficacy for antibody but the incon-
sistency in experimental results. When interpreting early studies,
one must also take into consideration that serum therapy was
typically performed with antibody preparations obtained from
a different species than the one studied (Glatman-Freedman
and Casadevall, 1998). In recent years, serological studies in
animals have shown species-specific antibody responses to
TB (Lyashchenko et al., 2008). Thus, transfer of antibody prepa-
rations between different species might be less effective than
within the same species, and it is difficult to conclude much
about the efficacy of antibodies from negative studies.
Following the fungal experience where the antibody response
is complex and includes the generation of both protective and
nonprotective antibodies, it is possible that the interstudy incon-
sistencies in the early studies reflected the types and amounts
of antibodies found in the polyclonal preparations. Indirect
evidence to support this notion comes from the observation
that protective and nonprotective mAbs to TB exist (Teitelbaum
et al., 1998). Heterogeneity of antibody responses has been
documented in human TB (Lyashchenko et al., 1998; Steingart
et al., 2009; Yu et al., 2012), and there is evidence that only
a minority of TB patients produce antibodies with the specificity
of a protective antibody to the mycobacterial polysaccharide
arabinomannan (AM) (Navoa et al., 2003). Furthermore, a recent
study demonstrated that sera from some TB contacts with high
IgG titers against tuberculin can block proliferation of PBMC
cultures with tuberculin, while sera from a few other contacts
with high titers stimulated proliferation (Encinales et al., 2010).
In contrast, no influence was observed with low-titer sera. These
observations highlight the complexity and heterogeneity of the
human humoral immune response against TB and emphasize
that studies have to be meticulously well-designed and elabo-
rate to identify and investigate protective functions of antibodies
against TB.
The Evidence that Humoral Immunity Contributes to
Protection against TB
In the past two decades, numerous studies have provided
evidence for the three criteria used to establish the efficacy of
humoral immunity against TB (Table 1). Eight independent labo-
ratories have now reported thatmAbs tomycobacterial antigens,
ranging from surface proteins to polysaccharides, modify the
course of experimental mycobacterial infection in mice to the252 Cell Host & Microbe 13, March 13, 2013 ª2013 Elsevier Inc.benefit of the host (Balu et al., 2011; Buccheri et al., 2009; Cham-
bers et al., 2004; Hamasur et al., 2004; Lo´pez et al., 2009; Pethe
et al., 2001; Teitelbaum et al., 1998; Williams et al., 2004; Table 1
and Table 2). Furthermore, three recent passive polyclonal IgG or
serum transfer studies within the same species (mice) or from
humans to mice have shown protection against TB (Guirado
et al., 2006; Olivares et al., 2006; Roy et al., 2005). Depending
on the study design and the types and targets of mAbs evalu-
ated, the measures of protection used were significantly in-
creased survival times (Chambers et al., 2004; Hamasur et al.,
2004; Teitelbaum et al., 1998), reduction of disease dissemina-
tion (Pethe et al., 2001), reduction of organ pathology (Balu
et al., 2011; Chambers et al., 2004; Lo´pez et al., 2009), and/or
reduced organ CFU (Balu et al., 2011; Buccheri et al., 2009; Ha-
masur et al., 2004; Lo´pez et al., 2009; Williams et al., 2004). One
study evaluated the effects of either mAb (2E9IgA1) plus IFN-g
treatment, mAb alone, or IFN-g alone compared to PBS controls
(Balu et al., 2011). Compared to controls, the combined mAb
plus IFN-g treatment reduced lung CFU counts 4 weeks post-
M.tb infection the most (>1 log[10]; p < 0.05). In contrast, there
was no significant CFU reduction by IFN-g alone (p = 0.23), while
reduction due to mAb was borderline significant (p = 0.06). This
study suggests a greater protective effect of an IgA mAb
compared to IFN-g but most of all demonstrates the potential
synergism between antibody and cytokine treatment in the
protection against TB. None of the mAb studies included a
comparison group of BCG-vaccinated mice, hindering the direct
comparison of quantitative effects of TB vaccines enhancing the
cell-mediated immunity. When comparing mAb transfer studies
to vaccination studies with BCG substrains which induce vari-
able organ CFU reduction ranging from 1/2 to 1 1/2 mean
log(10) 30 days after experimental M.tb infection in mice (Keyser
et al., 2011), some of the quantitative effects of mAbs were less,
some were similar, and some were superior to those described
for BCG vaccines (Table 2). We note that the existence of protec-
tive mAbs does not in itself prove that humoral immunity has
a role in the host defense against TB. For example, protective
mAbs have been described against antigens in both Listeria
monocytogenes andHistoplasma capsulatum that do not appear
to contribute to natural immunity against those pathogens (Edel-
son et al., 1999; Nosanchuk et al., 2003). Nevertheless, the fact
that such antibodies exist, together with further data discussed
below, provides strong evidence for the notion that antibodies
can be protective against TB.
The criterion of associating the presence and absence of
antibody with resistance and susceptibility to TB, respectively,
has also been met. Regarding the presence of antibody, mice
immunized with AM conjugate vaccines develop high IgG titers
against AM and are more TB resistant than control mice (Glat-
man-Freedman et al., 2004; Hamasur et al., 2003; Table 1 and
Table 3). In fact, one of these AM conjugate vaccines demon-
strated prolonged survival and reduced histopathological find-
ings comparable to BCG vaccine (Hamasur et al., 2003). Further-
more, BCG, many other mycobacterial antigen-based conjugate
vaccines, as well as DNA/RNA vaccines, elicit humoral immune
responses and improve the outcome of TB infection (Table 3).
Althoughmost of these vaccine studies conclude that protection
against TBwas based solely on cell-mediated immunity, they did
not evaluate antibody function. Only the study by de Vallie`re et al.
Table 1. Evidence of Antibody-Mediated Protection against TB
Criterion Evidence References
Passive antibody transfer studies Eight independent groups have shown protection
and/or modification of the course of mycobacterial
infection in mice with passive transfer of mAbs to
mycobacterial antigens (Table 2)
Balu et al., 2011; Buccheri et al., 2009;
Chambers et al., 2004; Hamasur et al., 2004;
Lo´pez et al., 2009; Pethe et al., 2001;
Teitelbaum et al., 1998; Williams et al., 2004
Three independent groups have recently shown
protection in mice with passive transfer of
immune polyclonal sera
Guirado et al., 2006; Olivares et al., 2006;
Roy et al., 2005
Antibody titer associated with
reduced susceptibility
AM-containing conjugate vaccine elicits antibody
response that reduces susceptibility to infection
(Table 3)
Glatman-Freedman et al., 2004;
Hamasur et al., 2003
BCG as well as M.tb antigen-containing conjugate
and DNA/RNA vaccines elicit cellular and humoral
immune responses and improve outcome of
infection (Table 3)
Chang-hong et al., 2008; de Vallie`re et al., 2005;
Giri et al., 2006; Glatman-Freedman et al., 2004;
Grover et al., 2006; Hamasur et al., 2003;
Huygen et al., 1996; Kohama et al., 2008;
Niu et al., 2011; Palma et al., 2008;
Teixeira et al., 2006; Xue et al., 2004
Increased susceptibility in hosts
with antibody deficits
Peak of childhood TB is temporally correlated
with nadir in maternal antibody
Beyazova et al., 1995; Cruz and Starke, 2007;
Donald et al., 2010
Lack of antibodies against certain mycobacterial
antigens is associated with TB dissemination in
children and adults
Boggian et al., 1996; Costello et al., 1992;
Dayal et al., 2008; Gupta et al., 1997;
Sada et al., 1990
Lack of early humoral immune response in
M.tb-infected nonhuman primates predicts
high likelihood for reactivation disease
Kunnath-Velayudhan et al., 2012
B cell-deficient mice are more susceptible to TB Maglione et al., 2008; Maglione et al., 2007;
Vordermeier et al., 1996
Polymeric IgR-deficient mice lose mycobacterial
antigen-specific IgA response in saliva and are
more susceptible to respiratory BCG infection
Tja¨rnlund et al., 2006
IgA deficiency increases susceptibility to
mycobacterial infection in mice
Buccheri et al., 2007; Rodrı´guez et al., 2005
Other Existence of mycobactericidal antibodies Conti et al., 1998
FcR-mediated phagocytosis promotes
phagolysosomal fusion
Armstrong and Hart, 1975
FcR-mediated phagocytosis increases
macrophage Ca2+ signaling and intracellular killing
Malik et al., 2000
IgG bound to BCG enhances oxygen release in
phagosomes and antimycobacterial activity of
alveolar macrophages
Suga et al., 1996
mAb, monoclonal antibody; AM, arabinomannan; M.tb, M. tuberculosis.
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induced antibodies promote critically enhancing effects on
both the innate and cell-mediated immune responses to myco-
bacteria, providing further evidence of protective antibody func-
tions against TB (de Vallie`re et al., 2005).
Regarding the absence of antibody, the peak age of vulnera-
bility for children coincides with a nadir in antibody to TB
(Beyazova et al., 1995; Cruz and Starke, 2007; Donald et al.,
2010). This relationship is further supported by a study demon-
strating an association between the lack of antibody to the
mycobacterial cell wall glycolipid lipoarabinomanna (LAM) with
disseminated TB in age-matched children (Costello et al.,
1992) (Table 1). Although these correlations do not necessarily
establish causality, it is noteworthy that patients with HIV-asso-
ciated TB, which tends to progress faster and frequently dissem-inates, also lack antibodies to LAM (Boggian et al., 1996).
Furthermore, serological studies have found lower antibody
levels against mycobacterial antigens in both children and adults
with miliary, meningeal, and pleural TB in contrast to localized
pulmonary TB (Dayal et al., 2008; Gupta et al., 1997; Sada
et al., 1990). These findings suggest that low-antibody titers
could increase the risk of TB dissemination.
There is also increasing evidence that mice with defective
humoral immunity are more susceptible to TB. There are four
studies with B cell-deficient mice in the literature. Two of them
report that such mice are more susceptible to experimental
infection (Maglione et al., 2007; Vordermeier et al., 1996).
Another study involving mouse challenge with M.tb followed by
isoniazid therapy and then rechallenge found no difference
between B cell-deficient and wild-type mice (CDC, 2012). InCell Host & Microbe 13, March 13, 2013 ª2013 Elsevier Inc. 253
Table 2. Studies Demonstrating Protective Function of Monoclonal Antibodies against Experimental TB in Mice
mAb (Isotype)
Target Antigen
(Type) Model
Organism/Antigen
Challenge (Route)
mAb Administration
(Timing to Infection) Change in CFU Biological Effect Quantitative Effect References
9d8 (IgG3) AM (capsular
polysaccharide)
Mouse (BALB/c
and C57BL/6)
M.tb (ae and i.t.) i.t. (simultaneous/
preincubated mAb
with M.tb)
4 Lungs, spleen,
and liver
Prolonged survival
and enhanced
containment of
M.tb within
granuloma centers
30%–60% of mAb-treated
mice survived >75 days
(33% over 220 days) versus
death in control mice within
30 days (p < 0.01)
Teitelbaum et al.,
1998
4057 (IgG3) HBHA (surface-
exposed protein)
Mouse (BALB/c) BCG (i.n.) i.n. (simultaneous/
preincubated mAb
with BCG)
4 Lungs
Y Spleen
Reduction of
disease
dissemination
Reduced spleen colonization
by 3 log(10) CFUs 3 weeks
postinfection in mAb-treated
mice compared to controls
(p value not stated)
Pethe et al., 2001
TBA61 (IgA) 16 kDa a-crystalin
(intracellular and
cell-wall protein)
Mouse (BALB/c) M.tb (ae and i.n.) i.n. (3 hr before and
3 or 6 days after)
Y Lungs CFU reduction
in early disease
Reduced lung colonization
by 1 log(10) CFUs 9 days
postinfection in mAb-treated
mice compared to controls
(p < 0.01)
Williams et al.,
2004
SMITH14 (IgG1) AM portion of
LAM (cell-wall
glycolipid)
Mouse (BALB/c) M.tb (i.v.) i.v. (simultaneous/
preincubated mAb
with M.tb or 1 hr
prior)
Y Lungs
Y Liver
YSpleen
CFU reduction
and prolonged
survival
Reduced lung, liver, and
spleen colonization by 1–2
log(10) CFUs 14 days
postinfection in mAb-treated
mice 1 hr prior to infection
compared to controls (p < 0.05
lungs and p < 0.01 liver and
spleen) and survival of 7–8/10
(75%) mAb-treated mice
versus 4/10 (40%) controls at
70 days (p < 0.01)
Hamasur et al.,
2004
MBS43 (IgG2b) MPB83 (cell-
wall and CF
protein)
Mouse (BALB/c) M. bovis (i.v.) i.n. (simultaneous/
preincubated mAb
with M. bovis)
4 Lungs
4 Liver
4 Spleen
Reduced lung
pathology and
prolonged survival
Twice the estimated amount
of normal lung tissue in mAb-
treated mice compared to
controls (p < 0.05) and 8/8
(100%) of mAb-treated mice
survived >38 days (end of
experiment) versus 0/8 (0%)
of control mice (death within
30–34 days) (p < 0.005)
Chambers et al.,
2004
(Continued on next page)
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Table 2. Continued
mAb (Isotype)
Target Antigen
(Type) Model
Organism/Antigen
Challenge (Route)
mAb Administration
(Timing to Infection) Change in CFU Biological Effect Quantitative Effect References
TBA61 (IgA) and
TBA84 (IgA)
16 kDa a-crystalin
(intracellular and
cell-wall protein)
and 38 kDa PstS-1
(CF protein)
Mouse (BALB/c) M.tb (i.t.) i.t. (mAb given 30 min
prior to infection)
Y Lungs (only
for TBA61)
Reduced lung
pathology (only
for TBA61)
Reduced lung colonization
by 200 3 103 CFUs 21 days
postinfection in mAb TBA61-
treated mice compared to
controls and TBA84-treated
mice (p < 0.05) and reduced
peribronchial inflammation
in TBA61-treated mice
compared to controls 21 days
postinfection (p < 0.05)
Lo´pez et al., 2009
TBA61 (IgA) 16 kDa a-crystalin
(intracellular and
cell-wall protein)
Mouse (BALB/c,
C57BL/6, and
C3H/HeJ)
M.tb (i.v.) i.n. and i.v. given at
3, 5, or 7 weeks as CIT
with INF-g, polyclonal
Ab against IL-4, and
mAbTBA61 in mice
treated for 4 weeks
with INH/R
Y Lungs in CIT-
treated mice
Prevention of TB
relapse in mice
treated with CIT
together with [
granuloma formation
and [ cyto- and
chemokine levels
Reduced lung colonization
by 3–4 log(10) CFUs 8 weeks
postinfection in CIT-treated
mice compared to controls;
strongest protection when CIT
given 5 weeks postinfection
(p = 0.001)
Buccheri et al.,
2009
2E9 (IgA1) 16 kDa a-crystalin
(intracellular and
cell-wall protein)
Mouse (CD89tg) M.tb (i.n.) i.n. with and without
INF-g (2 hr prior and
1 or 21 days post)
Y Lungs
Y Spleen
Reduced lung
pathology
Reduced lung colonization
by <1 log(10) CFUs 4 weeks
postinfection in mAb plus
INF-g-treated mice compared
to controls (p < 0.05) and
significantly reduced lung
granuloma formation in mAb-
treated mice (<10%) compared
to controls (45%; p < 0.001)
Balu et al., 2011
mAb, monoclonal antibody; CFU, colony-forming units; INF-g, interferon-gamma; IL, interleukin; Antigens: AM, arabinomannan; LAM, lipoarabinomannan; HBHA, heparin-binding haemaglutinin;
M.tb, M. tuberculosis; CF, culture filtrate; CIT, combined immunotherapy; INH/R, Isoniazid and Rifampin; ae, aerosol; i.n., intranasal; i.v., intravenous; i.t., intratracheal.
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Table 3. TB Vaccination Studies Documenting Induction of Ab Responses
Organism or
Antigen
(Adjuvant)
Vaccination
Route
Vaccination
Time Points
Experimental
Model
Organism
Challenge
(Route) Timing of Infection Immune Response CFU Biological Effect References
DNA encoding
Ag 85A (none)
i.m. 0, 3, 6 weeks Mice (BALB/c
and C57BL/6)
BCG and M.tb
(i.v. [BCG] and
ae [M.tb])
3–10 weeks after
last immunization
[ Ag 85A-specific IgG1,
IgG2a, and IgG2b, TNF-a
and GM-CSF;4 IL-4,
IL-6, and IL-10
Y Lungs Reduction in bacterial
load (comparable to
BCG)
Huygen et al.,
1996
AM (TT and
Ag85B)
s.c. (mice); s.c.
followed by i.n.
(guinea pigs)
0 (mice)
0, 24 days
(guinea pigs)
Mice (C57BL/6)
and guinea pigs
M.tb (i.n. or i.v.
for mice;
respiratory for
guinea pigs)
3–10 weeks after
last immunization
[ AM-specific IgG, and
T cell proliferation
4 Lungs
Y Spleen
Prolonged survival and
reduced pathology in
lungs and spleen
(comparable to BCG)
Hamasur et al.,
2003
AM (rEPA) s.c. 0, 2, 4 weeks Mice (BALB/c) BCG and M.tb
(i.v.)
Not stated [ AM-specific IgG Y Lungs
Y Spleen
Y Liver
Reduction in bacterial
load (1 week after
infection)
Glatman-
Freedman
et al., 2004
RNA/DNA
encoding
MPT83 (none)
i.m. 0, 3, 6, 9 weeks Mice (BALB/c) M.tb (i.v.) 4 weeks after
last immunization
[ MPT83-specific IgG,
IFN-g, and IL-2
Y Lungs Protection against
disease (inferior to
BCG)
Xue et al., 2004
BCG i.d. 0, 6 months Humans NA NA [ LAM-specific IgG NA Postvaccination Abs
enhanced the
capacity of neutrophils
and monocytes/
macrophages to (1)
internalize BCG, and
(2) inhibit mycobacterial
growth in vitro
de Vallie`re et al.,
2005
Ag 85A, 85B,
and 85AB
(DDA)
i.n. and s.c. 0, 2, 4 weeks Mice (BALB/c) M.tb (ae) 30 days after
last immunization
[ Ag 85A- and 85B-
specific IgA, IgG, IgG2,
IFN-g, IL-12, and IL-4
Y Lungs
Y Spleen
Protection against
disease (comparable to
BCG), strongest
response with i.n.
Ag85AB
Giri et al., 2006
DNA encoding
Ag 85B (none)
i.m. 0, 15, 30,
45 days
Mice (BALB/c) M. bovis 2 weeks after
last immunization
[ Ag 85B-specific IgG,
IgG1, and IgG2a, IFN-g
and TNF-a;4 IL-4
4 Lungs
Y Spleen
Partial reduction in
bacterial load
Teixeira et al.,
2006
DNA encoding
CFP10 and
CFP21 combined
with Ag85B
i.m. 0, 3, 6 Mice (C57BL/6) M.tb (i.v.) 4 weeks after
last immunization
[ IgG1 and IgG2a (not
indicated to which
antigens), [IFN-g,
IL-12, and CTL response
Y Lungs
Y Spleen
Reduction in bacterial
load (comparable to
BCG)
Grover et al.,
2006
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Table 3. Continued
Organism or
Antigen
(Adjuvant)
Vaccination
Route
Vaccination
Time Points
Experimental
Model
Organism
Challenge
(Route) Timing of Infection Immune Response CFU Biological Effect References
DNA encoding
Ag 85B (LTK63)
i.m. 0, 2 weeks Mice (C57BL/6) M.tb (i.v.) 4 weeks after
last immunization
[ Ag 85B-specific IgG,
mostly IgG2b, Y IFN-g,
IL-10, and TNF-a
compared to non-LTK
85B vaccine
Y Lungs Partial reduction in
bacterial load
Palma et al.,
2008
rHBHA (cholera
toxin)
i.n. 0, 2, 3, 4, 5 weeks Mice (BALB/c) BCG (ae) 2 weeks after
last immunization
[ HBHA-specific IgG
and IgA, and IFN-g
4 Lungs
Y Spleen
Partial reduction in
bacterial load 2 weeks
postinfection
Kohama et al.,
2008
DNA encoding
fusion protein
of Ag 85B and
ESAT6
i.m. 0, 2, 4, 6 weeks Mice (BALB/c) M.tb (i.v.) 4 weeks after
last immunization
[ Ag 85B-specific IgG1,
IgG2a, and IFN-g;4 IL-2
Y Lungs
Y Spleen
Reduced pathology
in lungs and spleen
Chang-hong
et al., 2008
Subunit vaccine
Mtb 10.4-HspX
s.c. 0, 3, 6 weeks Mice (C57 BL/6) M.tb (i.v.) 10 weeks after
last immunization
[ HspX-specific IgG1,
IgG2b, IgG2c, IFN-g,
and Il-17
Y Lungs Reduced pathology
in lungs and spleen
Niu et al., 2011
CFU, colony-forming units; INF-g, interferon-gamma; IL, interleukin; TNF-a, tumor necrosis factor-alpha; rHBHA, recombinant heparin-binding haemaglutinin (surface-exposed protein); Ag, antigen;
BCG, Mycobacterium bovis bacillus Calmette-Guerin; DDA, dimethyldioctadecylammonium bromide; i.m., intramuscular; s.c., subcutaneous; i.n., intranasal; i.d., intradermal; i.v., intravenous; ae,
aerosol; AM, arabinomannan; rEPA, recombinant Pseudomonas aeruginosa exotoxin A; TT, tetanus toxoid; CTL, cytotoxic T lymphocyte.C
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Perspectivecontrast, one study found that the pulmonary histopathology
was more pronounced in B cell knockout compared to wild-
type mice after low-dose M.tb infection (Bosio et al., 2000).
Despite comparable bacterial loads early after infection, B cell-
deficient mice had reduced pulmonary granuloma formation
and delayed dissemination of bacteria from lungs to peripheral
organs compared to wild-type mice. These effects could be
reconstituted with naive B cells, but not with serum fromM.tb-in-
fected wild-type mice. When interpreting such contradictory
data, one has to keep in mind that for many components of the
immune system, such as B cells, antibodies, and T cells and
macrophages, good, bad, or neutral effects can be demon-
strated, depending on many factors including the immune com-
petency of the host. In that respect, although a lack of granuloma
formation, especially in humans, is typically associated with in-
creased numbers of mycobacteria, decreased containment of
disease, and a higher likelihood of TB dissemination (Achkar
and Jenny-Avital, 2011; Di Perri et al., 1996; Saunders and
Cooper, 2000), granulomas may also help to promote infection
in some animal models, such as the zebrafish (Davis and Ramak-
rishnan, 2009; Rubin, 2009). The investigators of the latter two
studies concluded that humoral immunity had no role in the
defense against TB, although, when evaluating negative studies,
it is important to consider that an inability in measuring a differ-
ence does not necessarily imply that there is no difference.
We note that although antibodies are the products of B cells,
these cells in themselves can contribute to host defense against
mycobacterial disease through their numerous effects on the
inflammatory response (Almeida et al., 2011; Bosio et al., 2000;
Maglione and Chan, 2009; Maglione et al., 2007; Russo and
Mariano, 2010; Zhang et al., 2012). In this regard, we note
that whereas antibody-independent B cell effects are largely
accepted by the field, the historical controversy involves the
role of antibodies as B cell products, not B cells in themselves.
Another study indicating a role of antibodies showed that IgA-
deficient mice aremore susceptible to infectionwith BCG (Rodrı´-
guez et al., 2005). Similarly, polymeric IgR-deficient mice that
were vaccinated with the mycobacterial antigen PstS-1 had
lower PstS-1 specific IgA levels in their saliva and were more
susceptible to BCG infection then vaccinated wild-type mice
(Tja¨rnlund et al., 2006). Also providing supportive evidence for
a role of antibody protection in mucosal surfaces was the obser-
vation that IgA administration in the setting of IL-4 neutralization
and IFN-g administration conferred protection against M.tb in
mice (Buccheri et al., 2007). The observation that mice lacking
the g-chain of an activating receptor for the Fc portion of Abs
(FcgR) are more susceptible to M.tb infection and advanced
pulmonary disease than wild-type mice (Maglione et al., 2008)
provides further strong supportive evidence for a role of humoral
immunity in host defense against mycobacteria.
Mechanisms of Antibody-Mediated Protection
against M.tb
Despite being a facultative intracellular pathogen, M.tb is poten-
tially susceptible to various mechanisms of antibody-mediated
immunity. Opsonization through FcgR was shown to promote
phagolysosomal fusion (Armstrong and Hart, 1975) and to
increase macrophage Ca2+ signaling and intracellular killing
(Malik et al., 2000). IgG bound to BCG increased the release of258 Cell Host & Microbe 13, March 13, 2013 ª2013 Elsevier Inc.oxygen in the phagosomes of alveolar macrophages, suggesting
the enhancement of antimycobacterial macrophage activity by
antibody (Suga et al., 1996). Immune complexes that stimulate
FcεRII-CD23 receptors trigger cellular changes that promote
the killing of Toxoplasma gondii, another intracellular pathogen
(Vouldoukis et al., 2011), and stimulation of the same receptor
has been associated with antimycobaterial activity (Mossalayi
et al., 2009). Furthermore, the existence of potentially synergistic
functions between humoral and cell-mediated immunity against
TB is suggested by the observation that anti-mycobacterial anti-
bodies in BCG-vaccinated persons enhance both innate and
cell-mediated immune responses against mycobacteria (de Val-
lie`re et al., 2005), and that sera from TB contacts with high but
not low IgG titers against tuberculin can block proliferation of
PBMCcultureswith tuberculin (Encinales et al., 2010).Moreover,
a robust T cell response against intracellular pathogens such
as Chlamydia spp. and mycobacteria is enhanced by specific
antibody responses that can augment Th1 activation via FcR
by facilitating rapid uptake, processing, and presentation of anti-
gens (Igietseme et al., 2004).
Antibody can also contribute to the host defense against M.tb
by promoting the clearance of immunomodulatory antigens such
as LAM (Glatman-Freedman et al., 2000). In addition, there are
mechanisms shown in other intracellular pathogens that could
also apply to M.tb. Protective and nonprotective mAbs mediate
differences in gene expression for Cryptococcus neoformans
(McClelland et al., 2010), and agglutinating nonopsonic anti-
bodies have been shown to mediate bactericidal effects against
Streptococcus pneumoniae through quorum-sensing-related
mechanisms (Yano et al., 2011). Finally, antibodies that mimic
the action of fungal killer toxin have been shown to be bacteri-
cidal to M.tb (Conti et al., 1998). Although such antibodies are
unlikely to be present in M.tb infection, the fact that mycobacte-
ria can be killed directly by certain antibodies provides a prece-
dent for such a mechanism of antibody-mediated protection.
In addition to these direct mechanisms, antibodies can influ-
ence the outcome of mycobacterial infection through their ability
to modulate inflammation. Some antibodies, such as IgM, can
demonstrate proinflammatory properties through their ability to
activate complement (Ciurana et al., 2004), while other anti-
bodies, such as IgG, can demonstrate pro- or anti-inflammatory
properties depending on the antigen and FcR receptor engaged
(Ballow, 2011; Lux et al., 2010). Antibody-mediated activation of
complement in mycobacterial infection has been demonstrated
in several studies by various groups. Human IgG, and to a lesser
extent, IgM, was found to enhance complement binding to BCG
(Carroll et al., 2009). In TB patients, levels of serum IgG2 but not
IgM against LAM correlated positively with classical comple-
ment activation induced by BCG (Hetland et al., 1998). Further-
more, human IgG against mycobacterial antigens in bacterial
sonicates enhanced complement activation by M.tb and in-
creased phagocytosis of M.tb by macrophages (Manivannan
et al., 2012).
When the action of antibodies is analyzed from the context of
the damage-response framework, it is apparent how the pro- or
anti-inflammatory properties can be protective or deleterious
depending on the immune status of the host (Figure 1). M.tb is
pathogenic in hosts with either too much or too little inflamma-
tory response, as evidenced by disease states characterized
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Figure 1. Interpretation of the Potential Function of Pro- and Anti-
Inflammatory Antibodies against M.tb in the Context of the Damage-
Response Framework by Casadevall and Pirofski
(A) Potential effects of a proinflammatory antibody with enhanced inflamma-
tion leading on the one hand to the improvement from disseminated/miliary TB
in an immunocompromised host (left) to localized granuloma formation, and on
the other hand to progression from granuloma to caseous necrosis in the more
immunocompetent host (right).
(B) Potential effects of an anti-inflammatory antibody leading to worsening TB
dissemination in the immunocompromised host who has already reduced
inflammation (left), but improved containment of local disease from caseous
necrosis to granuloma formation in the more immunocompetent host with
a strong inflammatory response (right). LTBI, latent TB infection.
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Perspectiveby caseous necrosis or widespread dissemination, such as
miliary TB, respectively (Achkar and Jenny-Avital, 2011; Casade-
vall and Pirofski, 2003). In contrast, hosts that mount an
intermediate response can presumably control infection through
granuloma formation. From this synthesis it is apparent that anti-
bodies that are proinflammatory could help hosts that respond
with too little inflammation, while those that are anti-inflamma-
tory could help hosts with exuberant inflammatory responses
that result in tissue destructions.
Characteristics of Protective Antibodies to M.tb
The major antibody characteristics that contribute to protection
are specificity, affinity, and isotype. At this time relatively few
mAbs have been studied in detail, and it is not possible to
draw broad conclusions on the characteristics of protective
antibodies to M.tb. However, some themes are beginning to
emerge. At least six different antigenic determinants have been
shown to be targeted by protective antibodies (Table 2). Murine
mAbs of the IgM, IgG1, IgG3, and IgA isotype have each been
shown to protect against TB, implying that these constant
regions can mediate protection (Table 2). Evidence that theconstant region has an important role in protection comes from
the observation that an IgG3 to AM lost protective efficacy
when switched to IgG2a, although there were no side-by-side
comparisons of the parent and switched isotypes in the same
experiment (Schwebach, 2002). In addition, Williams et al.
showed that an IgA against the 16 kDa a-cristalin (TBA61) medi-
ated some protection against TB, as evidenced by reduced
mycobacterial burden in the lungs, while an IgG1 mAb (TB68)
against the same epitope had no effect (Williams et al., 2004).
The finding that some IgAs are protective against M.tb in pulmo-
nary infection is interesting given the importance of this isotype in
mucosal immunity. In this regard, Balu et al. reported that intra-
nasal administration of IgA1 mAb 2E9 and recombinant mouse
IFN-g significantly inhibited pulmonary H37Rv infection in mice
transgenic for human CD89, but not in CD89-negative littermate
controls, suggesting that binding to CD89 was necessary for the
IgA-mediated protection (Balu et al., 2011). At this time there is
no information on the role of affinity in antibody efficacy. Further-
more, given that studies of antibody-mediated immunity against
M.tb using defined reagents such as mAbs are at their infancy,
the role of complement and type of FcR activation necessary
for protection has not yet been investigated.
Antibody-Mediated Immunity against TB Could Enhance
Vaccine Efficacy
When one considers the older data (Glatman-Freedman, 2006;
Glatman-Freedman and Casadevall, 1998), the experience with
other pathogens such as fungi and Salmonella spp., the com-
plexity of antibody responses to mycobacteria, and other recent
studies as summarized in Table 1, the preponderance of evi-
dence indicates a role for humoral immunity in protection against
TB. Given that protective and nonprotective antibodies exist,
and that the antibody response to TB is heterogeneous, positive
studies are much more significant than negative studies. In fact,
negative studies are best interpreted to mean that the particular
serum or vaccine used did not result in antibody-mediated
protection in a specific setting, and such studies do not neces-
sarily speak to the general question of antibody efficacy against
TB. In contrast, positive studies provide evidence for the ability
of humoral immunity to contribute to the host defense against
TB. We therefore interpret the existing data to indicate that
induction of antibody-mediated immunity could enhance protec-
tive effects of TB vaccine approaches.
We propose that antibody-mediated immunity can have a
protective role against M. tb at various stages of infection. Based
on the published observation in the field, we note that several
mechanisms have already been established. Early in the course
of infection, protective antibodies could promote ingestion
by phagocytic cells and increased intracellular killing through
FcR-mediated phagocytosis, which can also enhance cellular
response through rapid uptake and processing of mycobacterial
antigens. Such antibodies could also activate complement,
which in turn can promote phagocytosis and inflammation. Anti-
bodies to cell-surface polysaccharides and lipopolysaccharides
could further mediate their clearance, and thus reduce their
capacity for detrimental effects on the immune response. Finally,
antibodies can modify the intensity of the inflammatory
response, and here their dual nature as pro- and anti-inflamma-
tory molecules could promote a bactericidal inflammatoryCell Host & Microbe 13, March 13, 2013 ª2013 Elsevier Inc. 259
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Perspectiveresponse and/or reduce the tissue-destroying effects of runaway
granuloma formation. In fact, antibodies could have different
roles in protecting immunologically naive hosts during initial
infection and in the setting of vaccination to protect against
infection. Naturally occurring antibody, in particular IgM, has
been shown to be critical against many infectious diseases (Ca-
sadevall and Pirofski, 2012b) and is likely to have an important
role in protection by facilitating an early inflammatory response.
In contrast, vaccine-induced IgG could be expected to function
differently through the engagement of FcR. Although the relative
importance of these effects is currently uncertain and may differ
from host to host, the fact that antibodies have the capacity to
powerfully affect all aspects of the interaction between myco-
bacteria and other components of the immune system suggests
that this arm of the adaptive immune response can make a deci-
sive contribution to the outcome of M.tb infection and should not
be ignored.
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